BroadOak Fund IV, LLC - 22 Jun 2021 Form 4 Insider Report for Codex DNA, Inc. (TBIO)

Role
10%+ Owner
Signature
/s/ Jennifer McNealey, as Attorney-in-Fact
Issuer symbol
TBIO
Transactions as of
22 Jun 2021
Net transactions value
$0
Form type
4
Filing time
23 Jun 2021, 16:05:22 UTC
Previous filing
17 Jun 2021
Next filing
07 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBIO Common Stock Conversion of derivative security $0 +1,319,045 +132% $0.000000 2,319,045 22 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TBIO Series Z Preferred Stock Conversion of derivative security $0 -500,000 -100% $0.000000* 0 22 Jun 2021 Common Stock 500,000 Direct F1
transaction TBIO Series A Preferred Stock Conversion of derivative security $0 -541,677 -100% $0.000000* 0 22 Jun 2021 Common Stock 541,677 Direct F1
transaction TBIO Series A-1 Preferred Stock Conversion of derivative security $0 -277,368 -100% $0.000000* 0 22 Jun 2021 Common Stock 277,368 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

BroadOak Fund IV, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each share of Series Z Preferred Stock, Series A Preferred Stock and Series A-1 Preferred Stock (collectively, the "Preferred Stock"), par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Preferred Stock into Common Stock had no expiration date.